6,7-dihydroxy Bergamottin (Synonyms: 6,7-DHB) |
| Katalog-Nr.GC11864 |
potent inhibitor of CYP3A4
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 145414-76-2
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
IC50: 25 μM
6,7-dihydroxy Bergamottin, also known as 6,7-DHB, is a potent inhibitor of cytochrome P4503A4 (CYP3A4) with an IC50 value of 25 μM. As a primary compound in grapefruit juice, 6,7-DHB is responsible for the blockade the activity of testosterone 6β-hydrolase.
CYP3A4 is an important enzyme, mainly found in both the intestinal wall and liver, which oxidizes small foreign organic molecules (xenobiotics), such as toxins or drugs.
In vitro: 6,7-DHB significantly blocked the testosterone 6β-hydrolase in human liver microsomes and human CYP3A4 expressed in Escherichia coli membrane in a time- and concentration-dependent manner. Furthermore, 6,7-DHB proved to be a potent NADPH- and time-dependent inhibitor of CYP3A4 [1]. 6,7-DHB concentration-dependently inhibited nifedipine (NFP) oxidation in HepG2-GS-3A4 cell, a cell line from hepatoblastoma with overexpression of human CYP3A4 [2].
In vivo: Male Wistar-ST rats were intraduodenally administered with 6,7-DHB at a dose of 3.4 mg/ml. After 4 hours, 6,7-DHB had no significant effects on the NFP plasma concentrations, suggesting that 6,7-DHB had no pharmacokinetic effect on the rats [3].
References:
[1]. Bellevue, F., Woster, P., Edwards, D., He, K., & Hollenberg, P. Synthesis and biological evaluation of 6′,7′-dihydroxybergamottin (6,7-DHB), a naturally occurring inhibitor of cytochrome P450 3A4. Bioorganic & Medicinal Chemistry Letters. 1997; 7(20): 2593-2598.
[2]. Araki, N., Tsuruoka, S., Hasegawa, G., Yanagihara, H., Omasa, T., & Enosawa, S. et al. Inhibition of CYP3A4 by 6′,7′-dihydroxybergamottin in human CYP3A4 over-expressed hepG2 cells. Journal of Pharmacy and Pharmacology. 2012; 64(12): 1715-1721.
[3]. Mohri, K., & Uesawa, Y. Effects of Furanocoumarin Derivatives in Grapefruit Juice on Nifedipine Pharmacokinetics in Rats. Pharmaceutical Research, 2001;18(2):177-182.
| Cas No. | 145414-76-2 | SDF | |
| Überlieferungen | 6,7-DHB | ||
| Chemical Name | 4-[[(2E)-6,7-dihydroxy-3,7-dimethyl-2-octenyl]oxy]-7H-fuoro[3,2-g][1]benzopyran-7-one | ||
| Canonical SMILES | O=C1C=CC2=C(OC/C=C(C)/CCC(O)C(C)(O)C)C3=C(OC=C3)C=C2O1 | ||
| Formula | C21H24O6 | M.Wt | 372.4 |
| Löslichkeit | ≤10mg/ml in ethanol;30mg/ml in DMSO;30mg/ml in dimethyl formamide | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6853 mL | 13.4264 mL | 26.8528 mL |
| 5 mM | 0.5371 mL | 2.6853 mL | 5.3706 mL |
| 10 mM | 0.2685 mL | 1.3426 mL | 2.6853 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *